Jesduvroq Approved for Anemia of CKD in Patients on Dialysis
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Diagnosis & Disease Information
FDA Approval Updates Enjaymo Indication for Cold Agglutinin Disease
Enjaymo is an immunoglobulin G subclass 4 monoclonal antibody.
Cognitive Scores Lower for Children With Iron Deficiency
Cognitive scores were lower in iron-deficient children after intervention, despite improvement in serum ferritin
Intravenous vs Oral Iron Does Not Increase CKD Risk
Investigators compared the therapies in a large national cohort of patients with normal kidney function.
October 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
MPR Weekly Dose Podcast #136
Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment.
FDA Panel Votes on Daprodustat for Anemia of Chronic Kidney Disease
The NDA was supported by data from the ASCEND clinical program, which included dialysis and nondialysis patients.
Zynteglo Approved as First Gene Therapy for Beta-Thalassemia
Zynteglo is a one-time gene therapy that works by adding functional copies of a modified form of the β-globin gene into a patient’s own hematopoietic stem cells.
Bifunctional Biologic Gets Orphan Drug Status for Paroxysmal Nocturnal Hemoglobinuria
KP104 is a bifunctional, first-in-class biologic that works by selectively inhibiting the alternative and terminal pathways in the complement system.
Beti-Cel, a Gene Therapy for Beta-Thalassemia, Gets FDA Panel Support
Beti-cel is an investigational one-time gene therapy that works by adding functional copies of a modified form of the beta-globin gene into a patient’s own hematopoietic stem cells.
